INTRODUCTION
============

Hirschsprung disease (HSCR), also known as congenital megacolon, is a life-threatening birth defect characterized by the absence of enteric ganglia in the submucosal and myenteric plexuses of the gastrointestinal tract[@B6]. It´s incidence varies from 1:5,000 to 1:10,000 live births with an overall male to female ratio of 3:1 to 5:1, particularly in those with short segments[@B16] ^,^ [@B21]. The diagnosis is established in 15% within the first month of life, in 40-50% in the first three months, in 60% at the end of the first year of age, and in 85% by four years[@B7]. The exact mechanism of HSCR is unknown, but it is clear that both genetic and environmental factors are involved[@B6]. Trisomy chromosome 21 is the most frequent chromosomal abnormality (\>90% cases) associated with HSCR disease[@B1]. Furthermore, it is associated with other congenital malformations in 5%-32% of cases including gastrointestinal tract, by CNS anomalies, hearing impairment and congenital anomalies of the kidney and urinary tract[@B28] ^,^ [@B31]. Perinatal and environmental risk factors for HSCR, such as vitamin A, maternal age, obesity, parity, hypothyroidism during pregnancy, medical drug use have been sparsely studied; however, the results have not been consistent[@B15] ^,^ [@B22] ^,^ [@B43].

HSCR can be inherited as an autosomal dominant, autosomal recessive and even as a polygenic disorder[@B1]. However, approximately in 30% of cases, it is associated with other malformations[@B8]. Genetic association analyses have identified 12 susceptibility loci including EDNRB, EDN3, GDNF, NTN, SOX10, PHOX2B, ECE1, KIAA1279/KBP, ZFHX1B, TTF-1 and NRG1[@B13]. However, variations in most of these loci are found mostly in the syndromic cases, in which HSCR is associated with other congenital malformation[@B1] ^,^ [@B8]. Linkage analyses of multiplex HSCR families established that the proto-oncogene rearranged during transfection (RET) is the major susceptibility gene to its development[@B8]. RET is a trans-membrane tyrosine kinase receptor which also involved in multiple endocrine neoplasia type 2 (MEN 2), causing medullary thyroid carcinoma, pheochromocytoma and primary hyperparathyroidism[@B18] ^,^ [@B25]. Among the variations of RET gene, rs2435357 and rs1800858 polymorphisms, locating in intron 1 and exon 2 of the RET gene, respectively, have been wildly investigated in HSCR. However, the results from different studies are controversial[@B8].

Therefore, we carried out current systemic review and meta-analysis to clarify the associations of the SNP rs2435357 and rs1800858 with susceptibility to HSCR.

METHOD
======

Literature search strategy
--------------------------

A comprehensive literature search was performed using PubMed, EMBASE, Google scholar, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical, WanFang and VIP database to identify all eligible studies evaluating the association of the RET rs2435357 and rs1800858 polymorphisms with HSCR risk up to June 30, 2018. The key words were as follows: (''Hirschsprung disease'' OR ''HSCR'' OR ''congenital megacolon'') AND (''Rearrange during Transfection'' OR ''RET Proto-oncogene'' OR ''Proto-Oncogene C-Ret'' OR ''RET gene'' OR ''Cadherin-Related Family Member 16'' OR ''Cadherin Family Member 12'') AND (''rs1800858'' OR ''c.135G\>A'' OR ''Ala45Ala'') AND (''rs2435357'' OR ''IVS1+9277C\>T'' OR ''c.73+9277C\>T'') AND ("polymorphism" OR "SNPs" OR "variation" OR "locus" OR "mutation"). The search was limited to human studies and published studies. In addition, the references list of relevant case-control studies and reviews were manually searched to identify any additional eligible studies. If two or more studies had the same or overlapping data, only the study with the largest sample or most recently published study was included in the meta-analysis.

Data collection
---------------

The data from the relevant published studies were extracted independently by two of the authors and entered them in a customized questionnaire. Then, the extracted data were compared, and disagreements were resolved through a discussion between the two researchers. For each eligible study, the following data were extracted: first author's name, publication year, country of origin, ethnicity, genotyping methods, source of controls (population-based and hospital-based), case and control numbers, genotype frequency of SNPs, minor allele frequency in controls, and Hardy-Weinberg equilibrium (HWE) in controls. The ethnicity was divided into Asian and Caucasian or others. In addition, studies was performed on different populations were considered as independent studies.

Inclusion and exclusion criteria
--------------------------------

Selected studies were included in the meta-analysis if they met the following criteria: 1) case-control or cohort studies; 2) evaluating the association of the rs2435357 and rs1800858 polymorphisms of RET gene with susceptibility to HSCR; 3) studies with sufficient data to perform a meta-analysis. Accordingly, studies with the following characteristics were excluded: 1) not case-control or cohort study; 2) no control population; 3) studies with insufficient available data or lacking of genotypes distribution data; 4) abstracts, comments, case reports, letters, editorials, reviews, and systematic reviews; 5) published studies containing duplicate data.

Statistical analysis
--------------------

The strength of association of RET rs2435357 and rs1800858 polymorphisms with HSCR risk was measured by odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance of the summary OR was determined using the Z-test. We used five models to evaluate associations of the RET rs2435357 and rs1800858 polymorphisms with HSCR risk including: allele model (B vs. A), homozygous model (BB vs. AA), heterozygous model (BB vs. BA), dominant model (BB+BA vs. AA), and recessive model (BB vs. AA+BA). The heterogeneity between studies was evaluated by chi-squared based Q test, in which a p-value less than \<0.05 was considered obvious heterogeneity. In addition, the I2 value was used to test the degree of heterogeneity, in which I2\<25%, no heterogeneity; I2 25-50%, moderate heterogeneity; I2\>50%, large or extreme heterogeneity[@B17]. The fixed effects model was used to pool ORs and 95% confidential interval (CI) when there was no significant heterogeneity. Otherwise, the random effects model (the DerSimonian and Laird method) was used. Hardy-Weinberg equilibrium was assessed by the goodness-of-fit Chi-square test. A sensitivity analysis was mainly performed by omission of a single study each time to assess the stability of obtained pooled ORs. In addition, sensitivity analyses were performed by omission HWE-violating studies. The potential publication bias was estimated by the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). In addition, Funnel plot asymmetry was further assessed by the method of Egger's linear regression test, in which p\<0.05 was considered a significant publication bias. The quality of genotype data was estimated by Hardy-Weinberg equilibrium (HWE) and low quality studies deviated from HWE were excluded in the sensitivity analysis. All the tests in this meta-analysis were conducted with Comprehensive meta-analysis CMA software (version 2.0; College Station, TX). P-values\<0.05 were considered statistically significant. Ethical approval was not necessary, as this was a meta-analysis based on previous studies, and no direct handing of personal data or recruitment of participants.

RESULTS
=======

Study characteristics
---------------------

Following the online search of multiple databases, 131 potentially relevant publications were retrieved. As shown in [Figure 1](#f1){ref-type="fig"}, after excluding the duplicates, 89 publications were remained. Among them, 69 publications were excluded because they were irrelevant, reviews/abstracts, not about human subjects, or not published in English. Finally, 20 case-control studies, including nine with 1,136 HSCR cases 2,420 controls for rs2435357 [@B3] ^,^ [@B14] ^,^ [@B19] ^,^ [@B27] ^,^ [@B30] ^,^ [@B32] ^,^ [@B40] ^,^ [@B41] ^,^ [@B42], and ten with 917 HSCR cases 1,159 controls for rs1800858 [@B5] ^,^ [@B9] ^,^ [@B10] ^,^ [@B12] ^,^ [@B23] ^,^ [@B24] ^,^ [@B30] ^,^ [@B34] ^,^ [@B37] ^,^ [@B39] were included. The characteristics of each study are summarized in [Table 1](#t1){ref-type="table"}. Among 18 case-control studies, 14 were conducted in Asians and four in Caucasians. All the included studies were published between 2003 and 2017. The HSCR cases sample size ranged from 16 to 362. Genotyping methods used included PCR, PCR-RFLP, TaqMan assay, and PCR-HRM. Fourteen matching for the controls were population-based, two were hospital-based, and two did not stated. All studies showed that the distribution of genotypes in the control group was in agreement with the HWE (p\<0.05), except for two studies[@B22] ^,^ [@B23] for rs2435357 and two[@B28] ^,^ [@B29] for rs1800858 polymorphisms.

FIGURE 1Flow chart depicting exclusion/inclusion of individual studies for meta-analysis

TABLE 1Main characteristics of studies included in this meta-analysisFirst Author/YearCountry (Ethnicity)Genotyping TechniqueSOCCase/ControlCasesControlsMAFsHWEGenotypesAlleleGenotypesAllelers2435357    TTTCCCTCTTTCCCTC  Zhang 2007China (Asian)PCRHB99/132572814142562962411201440.5450.544Arnold 2008European\*TaqManHB62/3012272351702141418420.7000.542Miao 2010China (Asian)PCRHB315/352228652252110962169952933590.5500.390Phusantisampan 2012Thailand (Asian)PCR-RFLPHB68/12047147108283164251261140.4750.447Prato 2009Italy (Caucasian)PCRHB22/851165281633250381320.7760.435Zhang 2015China (Asian)TaqManNS59/59421611001813301656620.5250.88076/595915213319Gunadi 2016Indonesia (Asian)PCR-RFLPNS93/13667224156302783261371350.4960.010Yang 2017China (Asian)TaqManPB362/144820912627544180329802317146014360.495=0.001Li 2017China (Asian)TaqManNS99/1146927316533195837961320.5780.641rs1800858    GGAGAAGAGGAGAAGA  Fitze 2003German (Caucasian)NSHB80/1201030405011065478177630.2620.899Garcia-Barcelo 2005China (Asian)PCR-RFLPHB172/19414401186827658100362161720.4430.536Burzynski 2004Netherland (Caucasian)NSHB105/1262127576914177409184580.2300.242Zhang 2005China (Asian)PCRHB16/40211352715121342380.4750.011Du 2006China (Asian)PCRHB94/12243357411471388211441300.532=0.001Liu 2008China (Asian)LDRPB116/144114263641684273291571310.4540.789Saryono 2010Indonesia (Asian)PCR-RFLPPB54/46523263375103065230.4560.033Liu 2010China (Asian)PCRHB125/148124568691814375301611350.4560.794Tou 2011China (Asian)PCRHB123/1681032815219452853110320.4370.716Phusantisampan 2012Thailand (Asian)PCR-RFLPHB68/12036239954140512936230.4540.117[^2]

Quantitative data synthesis
---------------------------

### rs2435357

[Table 2](#t2){ref-type="table"} listed the main results of the meta-analysis of rs2435357 polymorphism in the RET proto-oncogene and HSCR risk. We pooled all the ten case-control studies to assess the overall association of rs2435357 polymorphism with HSCR risk. Overall pooled analysis suggest a significant association between rs2435357 polymorphism and HSCR risk in overall estimations under all five genetic models, i.e., allele (C vs. T: OR=0.230, 95% CI 0.178-0.298, p=0.001, [Figure 2](#f2){ref-type="fig"}A), homozygote (CC vs. TT: OR=0.079, 95% CI 0.048-0.130, p=0.001); heterozygote (CT vs. TT: OR=0.149, 95% CI 0.048-0.130, p=0.001); dominant (CC+CT vs. TT: OR=0.132, 95% CI 0.098-0.179, p=0.001); and recessive (CC vs. CT+TT: OR=0.239, 95% CI 0.161-0.353, p=0.001).

TABLE 2Results of the association of RET polymorphism with OA riskSubgroupGenetic ModelType of ModelHeterogeneityOdds RatioPublication BiasI2 (%)PHOR95% CIZtestPORPBeggsPEggersrs2435357          OverallC vs. TRandom74.18=0.0010.2300.178-0.298-11.129=0.0010.8580.209CC vs. TTRandom60.850.0060.0790.048-0.130-10.008=0.0010.3710.178CT vs. TTRandom58.020.0110.1490.108-0.205-11.670=0.0011.0000.156CC+CT vs. TTRandom59.290.0090.1320.098-0.179-13.220=0.0010.3710.068CC vs. CT+TTRandom52.170.0270.2390.161-0.353-7.184=0.0010.1070.219rs1800858          OverallA vs. GRandom89.58=0.0015.5943.653-8.8777.679=0.0010.2100.469AA vs. GGRandom86.57=0.0018.4533.783-18.8905.203=0.0010.5910.934AG vs. GGRandom88.56=0.0011.2380.575-2.6660.5470.5851.0000.883AA+AG vs. GGRandom83.71=0.0013.4691.881-6.3963.984=0.0010.5910.800AA vs. AG+GGRandom83.23=0.0016.1203.608-10.3816.720=0.0011.0000.798

FIGURE 2Forest plots of rs2435357 and rs1800858 polymorphisms in the RET gene and HSCR risk: A) rs2435357 (allele model: C vs. T); B) rs1800858 (heterozygote model: AG vs. GG)

### rs1800858

[Table 2](#t2){ref-type="table"} listed the main results of the meta-analysis of rs1800858 polymorphism in the RET proto-oncogene and HSCR risk. Overall pooled analysis suggest a significant association of rs1800858 polymorphism and HSCR risk under four genetic models, i.e., allele (A vs. G: OR=5.594, 95% CI 3.653-8.877, p=0.001); homozygote (AA vs. GG: OR=8.453, 95% CI 3.783-18.890, p=0.001); dominant (AA+AG vs. GG: OR=3.469, 95% CI 1.881-6.396, p=0.001); and recessive (AA vs. AG+GG: OR=6.120, 95% CI 3.608-10.381, p=0.001), but not under heterozygote model (AG vs. GG: OR=1.238, 95% CI 0.575-2.666, p=0.585, [Figure 2](#f2){ref-type="fig"}B).

Sensitivity analysis
--------------------

The sensitivity analysis was conducted by omitting each study in each genetic model or removing certain studies such as those studies that did not conform to HWE. After individual study omission, the corresponding pooled OR was not altered significantly. This indicates that our results are statistically robust under all five genetic models examining associations of rs2435357 and rs1800858 polymorphisms with HSCR risk.

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to assess the possible publication bias of included studies. The shapes of the Begg's funnel plot did not reveal any evidence of obvious asymmetry under all five genetic models. In addition, Egger's linear regression also did not show any significantly statistical evidence of publication bias for rs2435357 under all five genetic models, i.e., allele (C vs. T: P~Beggs~=0.858 and P~Eggers~=0.209), homozygote (CC vs. TT: P~Beggs~=0.371 and P~Eggers~=0.178, [Figure 3](#f3){ref-type="fig"}A), heterozygote (CT vs. TT: P~Beggs~=1.000 and P~Eggers~=0.156), dominant (CC+CT vs. TT: P~Beggs~=0.371 and P~Eggers~=0.068) and recessive (CC vs. CT+TT: P~Beggs~=0.107 and P~Eggers~=0.219). Moreover, the Egger's test did not reveal publication bias rs1800858 polymorphism under all five genetic models, i.e., allele (A vs. G: P~Beggs~=0.210 and PEggers=0.469), homozygote (AA vs. GG: P~Beggs~=0.591 and P~Eggers~=0.934), heterozygote (AG vs. GG: P~Beggs~=1.000 and P~Eggers~=0.883), dominant (AA+AG vs. GG: P~Beggs~=0.591 and P~Eggers~=0.800) and recessive (AA vs. AG+GG: P~Beggs~=1.000 and P~Eggers~=0.798, [Figure 3](#f3){ref-type="fig"}B).

FIGURE 3Funnel plot for the detection of the publication bias for association of rs2435357 and rs1800858 polymorphisms in the RET gene with HSCR risk;a random-effects model was used: A) rs2435357 (homozygote model: CC vs. TT); B) rs1800858 (recessive model: AA vs. AG+GG).

DISCUSSION
==========

The gene for RET proto-oncogene, members of the glial cell line-derived neurotrophic factor (GDNF) family, maps to chromosome 10q^11.21^, contains 21 exons and covers 60kbp DNA^36^. The RET proto-oncogene encode a trans-membrane receptor tyrosine kinase protein with an extracellular domain rich in cysteine and an intracellular domain enriched in tyrosine that is important in transferring cell growth and differentiation signals^33^. The RET proto-oncogene germline loss of function mutations are associated with the development of HSCR, while gain of function mutations are responsible for development of various types of human cancer, including medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2) and 2B, pheochromocytoma and parathyroid hyperplasia^4^. To date, several genotype-phenotype correlations have been defined in association of RET mutations with different variants of MEN2 syndrome including MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC)^38^.

Several studies have been published exploring the association of the rs2435357 and rs1800858 polymorphisms in RET proto-oncogene with HSCR risk. However, the results of those studies were inconsistent and inconclusive, due to the ethnic differences and small sample size. Therefore, meta-analysis as a powerful tool for summarizing the different studies results is needed to achieve a more comprehensive and reliable conclusion on both polymorphisms in order to provide further insights into this debated subject. This meta-analysis and systematic review, including ten studies with 1,136 cases 2,420 controls for rs2435357 and ten with 917 cases 1,159 controls for rs1800858 were identified and analyzed in this meta-analysis. We found that of rs2435357 and rs1800858 polymorphisms in RET gene are associated with the HSCR risk. These findings are consistent with the meta-analysis by Liang et al[@B20]. They performed a meta-analysis on association of rs2435357 polymorphism with five studies (566 cases and 719 controls) and rs1800858 polymorphism with nine studies (863 cases and 1,118controls) with HSCR risk. They found rs2435357 and rs1800858 polymorphisms of RET are associated with susceptibility to HSCR. However, their meta-analysis the sample size is rather small and not adequate enough to detect the possible associations.

Between-study heterogeneity is common in meta-analyses, and identifying potential sources of heterogeneity is an essential component of a meta-analysis[@B26] ^,^ [@B35]. The most potential sources of heterogeneity in a genetic association meta-analysis are study design, ethnicity, genotyping methods, source of controls, and so on[@B2] ^,^ [@B11] ^,^ [@B29]. Selection bias, although no publication bias was observed, is a possible major source of heterogeneity. Therefore, we have performed subgroup analysis and sensitivity analysis by removing HWE-violating studies to found out source of heterogeneity in this meta-analysis. However, heterogeneity before and after the subgroup analysis and process of individual study removing did not reduced or disappeared. Thus, this finding confirmed that the meta-analysis results were statistically robust and that our results were reliable and stable.

This study has two main advantages were as: first, this was the most accurate and comprehensive meta-analysis on rs2435357 and rs1800858 polymorphisms of RET with HSCR risk; second, no publication bias was observed in the present meta-analysis results indicating that our results might be unbiased. However, there were some limitations to this study that may have affected our conclusions. First, the present meta-analysis was limited by relatively small number of studies and sample size on both rs2435357 and rs1800858 polymorphisms, which thus leading to smaller studies in subgroup analysis and weaken statistical power; thus, needs further studies. Second, only studies on Asians and Caucasians populations were involved in this meta-analysis. This bias may exist because we could not determine the role of rs2435357 and rs1800858 polymorphisms in whole populations. Thus, studies on other ethnicities such as Africans and Latinos must be performed to determine the potential effects of ethnic variation on HSCR susceptibility. Third, we have included only the data of published studies, publication bias may be exist, although our results of publication bias tests showed no significance. Fourth, because relevant information was insufficient in the original data, we did not perform stratification analysis by other covariates such as age, gender and so on. This might has caused confounding bias. Finally, it is known that the HSCR has a multifactorial etiology of involving in gene-gene, and gene environment interactions. However, these interactions could not be investigated in the present meta-analysis due to no appropriate data.

CONCLUSION
==========

This meta-analysis suggested that the rs2435357 and rs1800858 polymorphisms in RET proto-oncogene may be associated with susceptibility to HSCR. However, because of the relatively small size of included studies, future large-scale studies on different ethnicity are needed to confirm these findings.
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